Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


CONTINUING MEDICAL EDUCATION INFORMATION

Release Date: November 15, 2013
Last Reviewed: November 13, 2013
Expiration Date: November 15, 2014
Time to Complete Activity: 15 minutes

TARGET AUDIENCE

This activity has been designed to meet the educational needs of physicians with an interest in Diabetes & Endocrinology, as well as other health care professionals.

STATEMENT OF NEED

This activity will supply up-to-date news information to practicing clinicians which can be integrated into practice and aims to increase professional competency.

EDUCATIONAL OBJECTIVES

Upon proper completion of this activity, participants should be better able to:

  • Summarize the significance of the study in the context of clinical care.

DISCLOSURES

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Neither Paradigm Medical Communications, LLC, staff nor HealthDay's medical writer have financial relationships to disclose.

Peer reviewer, Cynthia Haines, M.D., has the following financial relationships to disclose:

  • Salary/Ownership Interest (stocks, stock options, or other ownership interest) - GlaxoSmithKline (Spouse)
Lower Glucose Threshold for T2DM Prevention Ups Costs
For the conventional benchmark of $50,000 per QALY, a threshold of 105 mg/dL is cost-effective

FRIDAY, Nov. 15, 2013 (HealthDay News) -- Although lowering the threshold for a normal fasting plasma glucose would identify more adults at high risk for developing type 2 diabetes, intervention costs would increase, according to research published online Oct. 17 in Diabetes Care.

Xiaohui Zhuo, Ph.D., of the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined data from the National Health and Nutritional Examination Survey for individuals without diabetes in the United States, aged 45 years and older. The authors used a simulation model to assess the cost-effectiveness of using various fasting plasma glucose thresholds to identify adults at high risk for type 2 diabetes.

The researchers found that the cost per lifetime quality-adjusted life-year (QALY) gained increased as the fasting plasma glucose threshold was lowered ($30,100 at 115 mg/dL, $32,900 at 110 mg/dL, $42,300 at 105 mg/dL, $60,700 at 100 mg/dL, $81,800 at 95 mg/dL, and $115,800 at 90 mg/dL).

"Lowering the fasting plasma glucose threshold leads to a greater health benefit of diabetes prevention but reduces the cost-effectiveness," the authors write. "Using the conventional benchmark of $50,000 per QALY, a threshold of 105 mg/dL or higher would be cost-effective."

Abstract
Full Text (subscription or payment may be required)


To earn CME credits for reading this article, click here

Copyright © 2013 HealthDay. All rights reserved.

September 30, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

'Just-in-Time' Methodology Can Reduce Patient Waiting Times

Insulin Increases Resting-State Functional Connectivity in T2DM

AACR: Obese in Adolescence, Colon Cancer in Later Life?

Pediatricians Endorse IUDs, Implants for Teen Birth Control

ESICM: Fenoldopam Offers Limited Benefit After Cardiac Sx

Daytime Cholecystectomy May Be Better for Acute Cholecystitis